Becton puts $25 million into TriPath in cancer test deal
This article was originally published in Clinica
Executive Summary
TriPath Imaging has come to the attention of a major company for the second time as it forms an agreement to develop and commercialise cancer tests for Becton Dickinson. Becton will invest $25 million into the cancer screening company in exchange for 2.5 million shares. Less than a year ago, Roche Holdings invested $43 million in TriPath. Shares in TriPath leapt 37% to $8.30 on news of the latest deal.